Overview
- New investor Innovation Industries led the upsized Series D, with Partners in Equity, Invest-NL, EQT Life Sciences and Health Innovations participating.
- ViCentra says the proceeds will scale manufacturing, support FDA filing activities for U.S. entry, and fund the European rollout of Kaleido 2 in early 2026, initially in France and Germany.
- The company reports stronger-than-expected uptake in Germany, France and the Netherlands, with more than 800 German patients holding prescriptions and awaiting supply, according to the CEO.
- Following the close, ViCentra placed about $4 million in equipment orders and expects unconstrained supply by next spring as production capacity ramps.
- Kaleido offers rechargeable dual pumps, short or long tubing wear options and integration with Dexcom G6/G7 and Diabeloop algorithms, entering a crowded market led by incumbents as GlobalData forecasts insulin pumps to surpass $16 billion by 2034.